T
Thierry Facon
Researcher at university of lille
Publications - 594
Citations - 40256
Thierry Facon is an academic researcher from university of lille. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 84, co-authored 543 publications receiving 34919 citations.
Papers
More filters
Journal ArticleDOI
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Michel Attal,Jean-Luc Harousseau,Anne-Marie Stoppa,Jean-Jacques Sotto,Jean-Gabriel Fuzibet,Jean-François Rossi,Philippe Casassus,Hervé Maisonneuve,Thierry Facon,Norbert Ifrah,Catherine Payen,Régis Bataille +11 more
TL;DR: The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001).
Journal ArticleDOI
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San-Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,William S. Dalton,Anthony Boral,Dixie Lee Esseltine,Jane B. Porter,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
Journal ArticleDOI
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Meletios A. Dimopoulos,Andrew Spencer,M. Attal,H. Miles Prince,Jean Luc Harousseau,Anna Dmoszynska,Jesús F. San Miguel,Andrzej Hellmann,Thierry Facon,Robin Foà,Alessandro Corso,Zvenyslava Masliak,Marta Olesnyckyj,Zhinuan Yu,John Patin,Jerome B. Zeldis,Robert Knight +16 more
TL;DR: Lenalidomide plus dexamethasone is more effective than high-dose dexamETHasone alone in relapsed or refractory multiple myeloma.
Journal ArticleDOI
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal,Valérie Lauwers-Cances,Gerald Marit,Denis Caillot,Philippe Moreau,Thierry Facon,Anne-Marie Stoppa,Cyrille Hulin,Lofti Benboubker,Laurent Garderet,Olivier Decaux,Serge Leyvraz,Marie-Christiane Vekemans,Laurent Voillat,Mauricette Michallet,Brigitte Pegourie,Charles Dumontet,Murielle Roussel,Xavier Leleu,Claire Mathiot,Catherine Payen,Hervé Avet-Loiseau,Jean-Luc Harousseau +22 more
TL;DR: Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma.
Journal ArticleDOI
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau,Michel Attal,Philippe Moreau,Catherine Charbonnel,Frédéric Garban,Cyrille Hulin,Serge Leyvraz,Mauricette Michallet,Ibrahim Yakoub-Agha,Laurent Garderet,Gerald Marit,Lucienne Michaux,Laurent Voillat,Marc Renaud,Bernard Grosbois,Gaelle Guillerm,Lotfi Benboubker,Mathieu Monconduit,Catherine Thieblemont,Philippe Casassus,Denis Caillot,Anne-Marie Stoppa,Jean-Jacques Sotto,Marc Wetterwald,Charles Dumontet,Jean-Gabriel Fuzibet,Isabelle Azais,Véronique Dorvaux,Marc Zandecki,Régis Bataille,Stephane Minvielle,Jean-Luc Harousseau,Thierry Facon,Claire Mathiot +33 more
TL;DR: In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival and have implications for the design of risk-adapted treatment strategies.